SmartCRT™ Technology

MultiSite Pacing
RESONATE™ X4
MultiSite Pacing
RESONATE™ X4
MultiSite Pacing
RESONATE™ X4

Options to maximize response.

MultiSite Pacing (MSP) with up to 13.3 years projected longevity with EnduraLife Battery Technology.*

The MultiSite Pacing feature-related complication-free rate at 180 days post MultiSite Pacing on is 99%.

51.3% of the non-responders at 6 months converted to responders at 12 months.1

RECEIVE PRODUCT UPDATES

Technology Overview

MultiSite pacing provides additional options for non-responders. 

Easily tailor device therapy to your patients' needs without lead repositioning.

  • 216 MultiSite pacing vector combinations
  • SmartVector test provides automated vector recommendations
  • SmartOffset test provides automated timing recommendations

Boston Scientific's MultiSite Pacing enables 3 ventricular pacing pulses, separated by optional offsets

Single site LV pacing: 2 ventricular pacing pulses, separated by an optional offset.

MultiSite LV pacing: 3 ventricular pacing pulses, separated by optional offsets.

SMART-MSP Study

A prospective, single-arm, multi-center, post-approval study with 584 patients in the US. 

  • SMART-MSP exceeded its endpoints
    • Safety Endpoint: The MSP feature-related complication-free rate at 180 days post MSP on is 99% (vs. goal of 90%).
    • Effectiveness Endpoint: 51% of the non-responders at 6 months converted to responders at 12 months (vs. goal of 5%).

Additional findings

  • MSP pacing with the E4 proximal pacing electrode in the ACUITY X4 LV lead is associated with a higher response rate (64.5% vs 38.6%) in patients that were non-responders at 6 months.
  • SMART MSP has minimal impact to battery life. Programmer estimate of remaining battery life*:
    • Pre-MSP @ 6m 8.9 ±  2.1 years
    • Post-MSP @ 12m 8.1 ±  2.2 years
Read trial results

SMART-MSP Effectiveness Endpoint

Dr. Samir Saba shares additional information related to the effectiveness of MultiSite Pacing from the SMART-MSP clinical trial. 

SMART-MSP Effectiveness Endpoint
Watch the full video

 

 

References

*Assumes: 2.0V RA, LV-only, 2.0V LV, 700Ω, 15% A pacing, 100% LV pacing, No LATITUDE, No Respiratory Rate Sensor, No Heart Failure Sensor Suite.

1. Saba S, et al. Safety and Effectiveness of Multi-Site Pacing in Initial Non-Responders to Conventional Cardiac Resynchronization Therapy. LBCT presented at: 2021 Heart Rhythm Society; July 2021; Boston, MA.

^Data are Mean ± SD 

Top